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Background: Recombinant protein-based therapeutics have become indispensable for the treatment of many
diseases. They are produced using well-established expression systems based on bacteria, yeast, insect and mammalian
cells. The majority of therapeutic proteins are glycoproteins and therefore the post-translational attachment of sugar
residues is required. The development of an engineered Escherichia coli-based expression system for production of human
glycoproteins could potentially lead to increased yields, as well as significant decreases in processing time and costs.
Results: This work describes the expression of functional human-derived glycosyltransferase UDP-GalNAc:polypeptide
N-acetylgalactosaminyltransferase 2 (GalNAcT2) in a recombinant E. coli strain.
For expression, a codon-optimised gene encoding amino acids 52–571 of GalNAcT2 lacking the transmembrane
N-terminal domain was inserted into a pET-23 derived vector encoding a polyhistidine-tag which was translationally
fused to the N-terminus of the glycosyltransferase (HisDapGalNAcT2). The glycosyltransferase was produced in E. coli
using a recently published expression system. Soluble HisDapGalNAcT2 produced in SHuffle® T7 host cells was purified
using nickel affinity chromatography and was subsequently analysed by size exclusion chromatography coupled to
multi-angle light scattering (SEC-MALS) and circular dichroism spectroscopy to determine molecular mass, folding state
and thermal transitions of the protein. The activity of purified HisDapGalNAcT2 was monitored using a colorimetric assay
based on the release of phosphate during transfer of glycosyl residues to a model acceptor peptide or, alternatively,
to the granulocyte-colony stimulating growth factor (G-CSF). Modifications were assessed by Matrix Assisted Laser
Desorption Ionization Time-of-flight Mass Spectrometry analysis (MALDI-TOF-MS) and Electrospray Mass Spectrometry
analysis (ESI-MS). The results clearly indicate the glycosylation of the acceptor peptide and of G-CSF.
Conclusion: In the present work, we isolated a human-derived glycosyltransferase by expressing soluble HisDapGalNAcT2
in E. coli. The functional activity of the enzyme was shown in vitro. Further investigations are needed to assess the potential
of in vivo glycosylation in E. coli.
Keywords: Protein expression, Escherichia coli, Glycosyltransferase GalNAcT2, Erv1p/PDI co-expression, in vitro glycosylation,
Filgrastim, Recombinant glycosyltransferase, Enzymatic activity glycosyltransferase, Secondary structure glycosyltransferaseBackground
Recombinant protein therapeutics comprise a significant
part of approved biotechnology-based medicines. Produc-
tion systems for recombinant proteins include bacteria,
yeast, insect and mammalian cells. Bacterial expression
systems for recombinant human-derived proteins are
widely used, but limited as most bacteria lack certain post-
translational modification (PTM) mechanisms, including
those for glycosylation [1]. In general, glycoproteins are* Correspondence: gaisser@hochschule-bc.de
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unless otherwise stated.produced in eukaryotic cell lines such as Chinese Hamster
Ovary (CHO), murine myeloma (NS0) or Baby Hamster
Kidney (BHK) [2]. Proteins stabilised by multiple disulfide
bonds are preferentially expressed in eukaryotic CHO,
yeast and insect cells, a production process that is often
time consuming and cost-intensive [3].
About a third of the currently approved recombinant
protein therapeutics are produced in E. coli strains [4].
The use of bacteria as expression hosts provides many
advantages such as rapid growth, low-cost media, a ver-
satility of cloning tools combined with the potential to
produce compounds with high yield and quality [4,5].
So far, E. coli-based systems have been employed toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment of engineered strains allowing the expression of
complex therapeutics including correct folding, disulfide
bond formation, and glycosylation modifications are highly
desirable and may potentially lead to a significant decrease
in process time and costs [2,6].
Glycosylation represents one of the most common post-
translational modifications, with N- and O-linked glycosyl-
ation requiring the activity of specific glycosyltransferases
[2,7]. N-glycosylations take place on an amide nitrogen
of the amino acid asparagine and O-glycosylations on
mucin are initiated by the addition of the monosacchar-
ide N-acetylgalactosamine to the hydroxyl group of the
amino acids serine or threonine [8-11]. The presence,
composition and pattern of glycosylation potentially influ-
ence various parameters such as glycoprotein functional
activity, folding, stability and immunogenicity [6,12]. Vari-
ous strategies have been pursued to isolate glycoengineered
E. coli strains including the functional transfer of glyco-
sylation pathways [6]. As an example, the production of
eukaryotic N-glycoproteins has been demonstrated in E.
coli engineered to express the N-glycosylation machinery
of Campylobacter jejuni [11,13]. Similarly, the construction
of an engineered E. coli strain has been described to suc-
cessfully transfer glycans to target proteins by the expres-
sion of several heterologous glycosyltransferases from
Saccharomyces cerevisiae in combination with the bacterial
oligosaccharyltransferase PglB from C. jejuni [13]. The
presence of O-linked glycosylation reactions in various
bacterial strains such as Neisseria and Acinetobacter [14,15]
further emphasises the future potential of glycoengineered
bacteria as cell factories in industrial production pro-
cesses [6]. Recently, a human sialyltransferase has been
expressed successfully in optimised E. coli strains carrying
mutations that provide an increased oxidative cytoplasmic
environment or that co-express molecular chaperones [1].
The enzyme sialylates O-linked glycoproteins and the
activity of the sialyltransferase catalysing the transfer
of sialic acid onto an O-glycoprotein substrate has
been demonstrated in a high throughput assay [1].
More recently, it has been shown that the pre-
expression of the redox folding helper proteins sulfhydryl
oxidase Erv1p derived from S. cerevisiae and the mature
form of human protein disulfide isomerase PDI improves
the production of soluble recombinant proteins with
multiple disulfide bonds [16]. Erv1p represents a sulf-
hydryl oxidase and FAD-dependent catalyst of disulfide
bonds present in the inter-membrane space of mito-
chondria [16]. Increased production of active proteins
has been demonstrated in E. coli strains expressing
Erv1p in the cytoplasm [16]. PDI is an ER-located pro-
tein in eukaryotes with multiple functions including
disulfide bond formation, breakage and rearrangement
[3,17].The human-derived glycosyltransferase UDP-GalNAc:
polypeptide N-acetylgalactosaminyltransferase 2 (Gal-
NAcT2) catalyses the first step in mucin biosynthesis by
transferring N-acetylgalactosamine (GalNAc) from the
sugar donor uridine-5′-diphospho-N-acetylgalactosamine
(UDP-GalNAc) to serine and threonine residues [18,19].
GalNAcT2 is a typical type II transmembrane protein
anchored in the membrane of the Golgi apparatus and
expressed differentially in cells and tissues such as human
placenta, kidney and liver [8,10,19,20]. The soluble form
of GalNAcT2 has been successfully produced in both Sf9
insect cells using a baculovirus vector as well as in yeast
strains and the activity of the purified transferase has been
confirmed [8,18,20,21]. More recently, it has been shown
that insect-cell derived GalNAcT2 can be used for in vitro
glycosylation of the clinically important drug granulocyte
colony stimulation factor (G-CSF) [22].
In this work, we describe the expression of functional
human-derived glycosyltransferase HisDapGalNAcT2 [8]
together with redox folding helpers [16] in the cytoplasm
of a recombinant E. coli strain. Our findings are a first step
towards establishing a glycosylation system in E. coli for
the transfer of GalNAc to G-CSF.
Results
Expression of HisDapGalNAcT2 in E. coli host strains
GalNAcT2 is a cysteine rich protein, with five disulfide
bonds maintaining the tertiary structure of both the ma-
ture [PDB:2FFV] and truncated soluble forms [8,10]. Initial
experiments to express the N-terminal fusion of the
soluble form of GalNAcT2 lacking the N-terminal trans-
membrane domain [8] were performed using the E. coli
expression strain Origami™ 2(DE3)pLysS, which carries
mutations in both the thioredoxin reductase (trxB) and
glutathione reductase (gor) genes to provide a less reducing
cytoplasmic environment and promote formation of disul-
fide bonds. Whole cell lysates, soluble and particulate frac-
tions were analysed by SDS-PAGE and a prominent protein
band with an apparent molecular weight of 60–64 kDa
was identified in whole cell lysates and pelleted material
(Figure 1A). Soluble protein was not detected. The protein
band of interest was excised and identified as HisDapGal-
NAcT2 using ESI MS analysis (data not shown).
To enable expression of soluble HisDapGalNAcT2, the
E. coli host strain SHuffle® T7 was used [3]. In addition to
the mutations in trxB and gor, this expression strain carries
a chromosomally integrated gene encoding the disulfide
bond isomerase DsbC [3]. Expression experiments with
E. coli SHuffle® T7 carrying pET23d(+)::HisDapGalNAcT2
were performed. In the SDS-PAGE assay the expected pro-
tein band was visible in pelleted cell fractions but soluble
protein was not detected (Figure 1B). The result was con-
firmed by immunoblot analysis (Figure 1C). To further
promote the production of soluble HisDapGalNAcT2,
AB
C
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Figure 1 SDS-PAGE and immunoblot analysis of HisDapGalNAcT2 expressed in E. coli. (A) Origami™ 2(DE3)pLysS cells carrying plasmid
pET23d(+)::HisDapGalNAcT2 were grown in LB medium at 37°C until OD600 0.5, at which point IPTG (final concentration 1 mM) was added and
cultures were incubated for a further 5 h. Cells were harvested by centrifugation, lysed and total cell lysate (T), the soluble protein fraction (S) and the
insoluble particulate fraction (P) were separated by SDS-PAGE and visualised by Coomassie staining. HisDapGalNAcT2 with an estimated mass of 61.7 kDa
(indicated by arrow) was not detected in the soluble (S) cell fraction, but a band of the correct size in the insoluble particulate (P) fraction (★) was excised
and further analysed by ESI-MS. (B) SHuffle® T7 cells harbouring either pET23d(+)::HisDapGalNAcT2 in the absence or presence of pMJS9 were grown in
EnPresso B medium. Fractionated cell samples were separated by SDS-PAGE and visualised by Coomassie staining (B) or immunoblotting (C) using a
mouse anti human GALNT2 antibody. Molecular weight markers (MW) are in kDa. HisDapGalNAcT2 with an estimated mass of 61.7 kDa (arrow)
was detected in soluble (S) and particulate (P) cell fractions. Commercially available rhGalNAcT2 (PC) and cell lysates of SHuffle® T7 pET23d(+)
and SHuffle® T7 pMJS9 cells (NC) were included as controls.
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proteins sulfhydryl oxidase Erv1p and protein disulfide
isomerase PDI (Lloyd W. Ruddock, pers. communication)
encoded by the pLysS [16] derived construct pMJS9 were
pre-expressed under the control of an arabinose promoter
[16] and the pET23d(+)::HisDapGalNAcT2-derived glyco-
syltransferase was subsequently induced. The presence of
soluble HisDapGalNAcT2 was detected in the soluble
cell fraction by SDS-PAGE and immunoblot analysis
(Figure 1B and C).
Protein purification
Several parameters were tested to establish optimal con-
ditions for purification of soluble HisDapGalNAcT2.
Preliminary experiments indicated that binding of His-
DapGalNAcT2 to Ni-NTA spin columns was impaired
by small amounts of imidazole. Omission of imidazole
from early steps of the purification protocol resulted in
improved binding of the soluble protein to the resin.
Immobilised metal affinity chromatography (IMAC) using
cobalt or nickel resins proved feasible (data not shown),
and in subsequent experiments Ni-NTA resin was used,
as described in the methods section. Fractions eluted from
the resin were collected, proteins were separated by SDS-
PAGE (Figure 2) and bands of approx. 60 kDa visible by
Coomassie staining were confirmed to be glycosyltrans-
ferase by immunoblotting (Figure 2B, lanes 8–12 and
Figure 2C lanes 9 to 11). Eluted fractions 9, 10 and 11
were pooled and determined to have a protein concentra-
tion of 0.86 mg/ml by BCA protein assay. This pooled sam-
ple with an estimated yield of 0.32 mg HisDapGalNAcT2
per gram of cell pellet was used for further analysis.
Analysis of purified HisDapGalNAcT2 by size exclusion
chromatography (SEC) and multi angle light scattering
(MALS)
Size exclusion chromatography with an inline multi-
angle light scattering detector (SEC-MALS) was used to
assess the presence of monomers, dimers and multimers
in the purified protein sample. The light scattering spectra
revealed a peak with 10.5 min retention time followed by
a second peak after 17 min (Figure 3A). The SEC-MALS
method was used to determine the molar mass across thepeak at 17 min retention time and the result of 61.7 (±1.2)
kDa was as expected for soluble monomeric HisDapGal-
NAcT2 (Figure 3A). Pairing this method with ultraviolet
spectroscopy (UV), the protein content in the eluted frac-
tion was recorded at 280 nm wavelength. The results of
the UV spectrum indicate a low content of proteins with a
molecular mass other than 61.7 (±1.2) kDa in the purified
sample (Figure 3B).
Circular dichroism (CD) spectroscopy analysis
The secondary structure and thermal transitions of
HisDapGalNAcT2 were assessed by CD spectroscopy
[23,24]. CD scans at far UV wavelengths (195-260 nm)
identified two characteristic minima at 208 nm and 220 nm
corresponding to α-helical protein features (Figure 4), indi-
cating that the purified HisDapGalNAcT2 was folded. This
notion was supported by the finding that commercially
available rhGalNAcT2 from NS0 murine myeloma cells
produced similar CD spectra (Figure 4A). Thermal unfold-
ing profiles of both glycosyltransferases were measured by
recording temperature-dependent molar ellipticity changes
[24] at 220 nm between 30°C and 65°C after heating the
respective protein solution. Based on the sigmoid graphs
shown in Figure 4, the thermal transition points of HisDap-
GalNAcT2 and rhGalNAcT2 were determined at 47.59°C
(±0.07) and 46.95°C (±0.12), respectively. These data
indicate a difference of about one degree with a higher
transition point for HisDapGalNAcT2 compared to the
commercially available rhGalNAcT2 (Figure 4B), sug-
gesting similar characteristics of the HisDapGalNAcT2
purified from E. coli and the glycosyltransferase pro-
duced in NS0 cells.
Analysis of HisDapGalNAcT2 enzymatic activity
To assess whether HisDapGalNAcT2 was enzymatically
active, a colorimetric glycosyltransferase assay was used
[25] (Figure 5). In this assay, N-acetylgalactosamine de-
rived from the sugar substrate UDP-GalNAc is added to
an acceptor substrate with the concomitant release of
nucleotide diphosphate UDP. A specific coupling phos-
phatase then hydrolyses UDP and the quantitative re-
lease of phosphate is detected using malachite based
reagents. Using peptide EA2 (PTTDSTTPAPTTK [10])
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Figure 2 Purification of HisDapGalNAcT2. SDS-PAGE (A) and immunoblot analyses (B and C) of flow-through, wash and elution fractions collected
during Ni2+-NTA purification (see Materials and methods) of soluble HisDapGalNAcT2. Insoluble HisDapGalNAcT2 (PC1) produced in Origami™ 2(DE3)
pLysS and verified by ESI-MS or His-Em-GFP (PC2, 27 kDa) are included as controls. (A) Coomassie staining detected protein bands with an expected
molecular weight (MW) of ca. 61.7 kDa in lanes 7–12. HisDapGalNAcT2 (arrows) was identified by immunoblotting using (B) specific polyclonal
anti human GALNT2 antibody or (C) penta-His antibody against the N-terminal His-Tag.
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and rhGalNAcT2 were measured as pmol of phosphate
released over time per μg of glycosyltransferase (pmol/
min/μg; Figure 5A-B). HisDapGalNAcT2 was found to
be an active glycosyltransferase with a specific activity of
139.6 ± 27.9 pmol/min/μg, approximately half the spe-
cific activity measured for the commercially available
rhGalNAcT2 (271.9 ± 12.4 pmol/min/μg) (Figure 5C).
To confirm that the acceptor substrate had indeed been
glycosylated by the glycosyltransferases, MALDI-TOF-
MS was performed (Figure 6A-D). Analysis of the un-
glycosylated EA2 acceptor peptide generated peaks with
m/z of 1317.7, consistent with its predicted molecular
weight of 1317.4 Da [26,27]. Peaks shifted by m/z 22 and
38 are consistent with sodium and potassium adducts of
the substrate, respectively (Figure 6A). Analysis of EA2
peptides from glycosyltransferase assays containing His-
DapGalNAcT2 (Figure 6B) or rhGalNAcT2 (Figure 6D)
revealed new peaks with m/z of 1520.7, 1723.8 and 1926.9,
consistent with the addition of the monosaccharide N-acetylgalactosamine (HexNAc; m/z 203) at one, two or
three sites in the peptide substrate.
The glycosyltransferase assay was then extended to test
glycosylation of a biopharmaceutically relevant substrate,
the granulocyte-colony stimulation factor (G-CSF) Filgras-
tim™ [UniProt:P09909], which contains only one putative
O-glycosylation site (Figure 5D-E). The specific activity of
HisDapGalNAcT2 was found to be 13.3 ± 0.7 pmol/min/
μg, again approximately half the specific activity measured
for rhGalNAcT2 (23.4 ± 8.6 pmol/min/μg; Figure 5F). The
presence of glycosylated Filgrastim™ in assay samples was
confirmed using ESI-MS analysis (Figure 7). These results
indicate that both glycosyltransferases, HisDapGalNAcT2
and rhGalNAcT2, transfer N-acetylgalactosamine to the
hydroxyl group of Thr166 in Filgrastim™ (Figure 7).
To assess partial misfolding of the protein e.g. due to
incorrectly linked disulfide bonds as a factor contribut-
ing to the difference in the specific activities measured,
samples of purified HisDapGalNAcT2 and commercially
available rhGalNAcT2 were investigated employing
AB
Figure 3 SEC-MALS analysis of the purified HisDapGalNAcT2 protein. (A) Light scattering spectrum of the eluted glycosyltransferase fraction in
50 mM Tris, 150 mM NaCl, pH 8. The orange line across the peak at the retention time of 17 min shows the molar mass distribution. (B) The UV-spectrum
measured at 280 nm shows a single peak representing monomers of HisDapGalNAcT2.
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conditions (Figure 5G-H). Denatured as well as un-
treated HisDapGalNAcT2 and rhGalNAcT2 migrate as
homogeneous single band at about 61.7 kDa in reducing
SDS-Gels (Figure 5G). Differences in the migrating be-
haviour of the proteins were observed with a double
band emerging under non-reducing conditions, an ef-
fect even more pronounced in the denatured sample of
HisDapGalNAcT2. Using densitometric analyses the
lower band represents an estimated 42.1% and the upper
band 57.9% of the total protein content under non-
reducing, denaturing conditions. Only a weak double
band was visible for rhGalNAcT2 (Figure 5H). This result
indicates the presence of different protein configurationsin the protein samples, however, the activity of purified
HisDapGalNAcT2 was clearly demonstrated.
Discussion
The expression of complex, correctly folded recombinant
proteins stabilised by disulfide bonds within the cytoplasm
of E. coli remains a challenging approach [3]. To isolate a
functional human-derived glycosyltransferase the E. coli
host strain Origami™ 2(DE3)pLysS proved unsuccessful.
Subsequent experiments were carried out using the ex-
pression strain SHuffle®T7, a derivative of the E. coli trxB
gor suppressor strain SMG96, which carries mutations
both in the thioredoxin reductase (trxB) and gluthathione
reductase (gor) [28]. The correct folding of the expressed
Figure 4 CD spectroscopy and thermal stability measurements of HisDapGalNAcT2 in comparison to rhGalNAcT2. (A) Far UV (195–260 nm)
spectra of HisDapGalNAcT2 (solid line) and rhGalNAcT2 (dashed line) indicating the folded status of the proteins at 21°C in 20 mM sodium phosphate
buffer at pH 7.3 CD data are reported as molar ellipticity (Θ) [24]. (B) Thermal unfolding profiles of HisDapGalNAcT2 (squares) and rhGalNAcT2 (circles)
were monitored at 208 nm.
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therefore aided by a less reducing cytoplasm and the
presence of a chromosomal copy of the disulfide bond
isomerase DsbC [3]. The strain has been engineered to
cytoplasmically express DsbC lacking its signal se-
quence that targets the protein to the periplasm [3].
The correct folding and soluble expression of recombin-













Figure 5 SDS-PAGE analysis and specific activity (SA) of HisDapGalNA
Filgrastim™. All reactions were initiated with 0.2 mM UDP-GalNAc and 1 m
min. (A, B, D, E) Absorbance at 620 nm plotted against glycosyltransferase
rhGalNAcT2. Denatured (5 min at 95°C) and untreated (10 min at room tem
by either reducing (G) or non-reducing (H) SDS-PAGE. The emerging doubhelper proteins [3,16]. As an example, work published
by Skretas et al. described the co-expression of chaper-
ones leading to improved production of recombinant
disulfide-bonded human sialyltransferase ST6GalNAcI
in E. coli [1]. However, co-expression of trigger factor,
DnaK/DnaJ, GroEL/GroES, and Skp did not always result
in increased soluble yields of ST6GalNAcI in engineered











cT2 compared to rhGalNAcT2 using the acceptor peptide EA2 or
M EA2 or 3 μg Filgrastim™ per well and proceeded at 37°C for 60
input in μg. (C, F) Comparison of the SA of HisDapGalNAcT2 and
perature) protein samples of both glycosyltransferases were separated








































Figure 6 MALDI-TOF-MS analysis of the glycosylation pattern of mucin EA2. MS spectra of (A, C) non-glycosylated EA2 in the absence of









Figure 7 ESI-MS/MS analysis of non-glycosylated and glycosylated Filgrastim™ (G-CSF). (A) Amino acid sequence of the substrate Filgrastim™
showing the tryptic digest peptides detected by ESI-MS/MS (yellow highlight, 58% coverage) and post-translationally modified amino acids (e.g. oxidation,
green). G-CSF peptides detected by ESI-MS/MS after treatment with glycosyltransferases (B) HisDapGalNAcT2 (42% coverage) or (C) of rhGalNAcT2
(48% coverage), showing the glycosylation site at Thr166 (red box and black arrow).
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provement and only insoluble HisDapGalNAcT2 was
identified in pelleted cell material. To produce soluble
HisDapGalNAcT2 in E. coli the expression system was
further optimised. The pre-expression of PDI and Erv1p
was required for the production of soluble HisDapGal-
NAcT2 in the E. coli strain indicating that the presence of
DsbC in the cytoplasm, as demonstrated by the SHuffle®
T7 strain without pMJS9, is not sufficient. During the
course of the expression experiments described in this
paper, the combination of SHuffle® T7 as expression
strain, the pre-expression of Erv1p and PDI [16], and the
use of EnPresso B medium for controlled glucose release
[29-31] proved to be successful. The calculated molar
mass of 61.7 kDa and the monomer status of the purified
HisDapGalNAcT2 were confirmed by SEC-MALS ana-
lysis. It has been suggested that the soluble forms of glyco-
syltransferases such as GalNAcT2 appear to be in the
monomer form [8]. CD-spectroscopy measurements were
performed comparing isolated HisDapGalNAcT2 with the
commercially available rhGalNAcT2 and the results indi-
cate a similar folding state for both glycosyltransferases, a
finding that is further supported by the observed similar
thermal transition points. The presence of different pro-
tein configurations in the protein samples were observed
in SDS-PAGE-assays carried out under non-reducing
conditions.
This result might help to explain the specific activity
of the tagged HisDapGalNAcT2 determined in the gly-
cosyltransferase assay which was lower than that of
rhGalNAcT2. Other potential contributing factors in-
clude differences in the N-terminal his-tag fusions of the
glycosyltransferases and storing conditions employed.
The N-terminal sequence of the glycosyltransferases is
not identical with a hexa-His-Tag translationally linked
to rhGalNAcT2 and a larger slightly alkaline N-terminal
HisDap purification tag comprising 17 amino acids
present in HisDapGalNAcT2, which might result in the
lower specific activity observed for this protein. Al-
though there is one potential glycosylation site in Gal-
NAcT2, glycosylation does not seem to be critical for
function as the unglycosylated form is enzymatically ac-
tive [8,21,32]. Therefore, lack of glycosylation might not
be the cause of the lower activity observed for Gal-
NAcT2 purified from E. coli.
The mucin type O-glycosylation of the acceptor sub-
strates EA2 and Filgrastim™ were analysed by mass
spectroscopy. The results indicate the presence of one
to three monosaccharide residues consistent with N-
acetylgalactosamine on the peptide EA2 and the glyco-
sylation of Thr166 of Filgrastim™. The association between
human GalNAcT2 and peptide substrate EA2 derived
from rat submandibular mucin [UniProt:Q62605] has
been studied in detail and the catalytic mechanisminvolved has been used as a model of O-glycosylation by
retaining glycosyltransferases [27,33]. GalNAcT2 has been
grouped among the early transferases that prefer non- and
monoglycosylated peptide substrates and are consequently
responsible for beginning stages of mucin glycosylations
[27]. Using a glycopeptide library it has been shown that
GalNAcT2 accepts various EA2 derived peptides carrying
different glycosylation patterns as substrates [27]. The pre-
ferred site for initial glycosylation has been identified as
the side chain hydroxyl of threonine at position 7 of the
EA2 peptide substrate [10,27].
Six different human recombinant GalNAc-transferases
have been studied identifying GalNAcT2 as the only
candidate for glycosylation of G-CSF [22]. The O-
glycosylation at Thr166 is not required for potency [34].
Filgrastim™, the non-glycosylated form of recombinant
G-CSF, is produced in E. coli and used to reduce the
duration of neutropenia in patients treated with cyto-
toxic chemotherapy and in patients undergoing therapy
followed by bone marrow transplantation [35]. It has
been concluded that the O-linked sugar chain decreases
polymerisation and contributes to the stability of G-CSF
[36]. Experiments are in progress to compare the expres-
sion of G-CSF in the presence and absence of HisDap-
GalNAcT2 studying the potential impact of a glycosyl
residue at Thr166 in E. coli.
Based on previously published results it has been sug-
gested that the glycosyltransferase displays a somewhat
relaxed specificity towards an alternative sugar substrate
[21,33]. The authors concluded that UDP-Galactose, also
available in E. coli, might serve as a naturally relevant
substrate for GalNAcT2 [6,21,33]. Based on the results
reported in this paper, in vivo experiments are under
way to study the transfer of glycosyl residues to the ac-
ceptor substrates EA2 and Filgrastim™ in E. coli.
Conclusion
The results presented here provide clear evidence for
the expression of an N-terminal His-tagged functional
human-derived glycosyltransferase UDP-GalNAc:poly-
peptide N-acetylgalactosaminyl-transferase 2 (HisDap-
GalNAcT2) in E. coli. The expression system described
in this work combines the use of E. coli strain SHuffle®
T7 with a less reducing cytoplasm and the co-expression
of redox folding helpers leading to the production of sol-
uble HisDapGalNAcT2 in special production medium.
The glycosyltransferase was isolated, the folding status
of the HisDapGalNAcT2 was assessed and the activity of
the protein in in vitro assays was shown. Further investi-
gations to study the in vivo activity of HisDapGalNAcT2
in E. coli are ongoing. The experiments in this paper
represent an approach to improve the understanding of E.
coli-based expression systems for the production of human
glycoproteins and to widen the future use of engineered
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recombinant glycoproteins.Materials and methods
Bacterial strains
The Escherichia coli strains NovaBlue (Novagen, Merck
Millipore, Germany), SHuffle®T7 (C3026H, New England
Biolabs, Germany) and Origami™ 2(DE3)pLysS (Novagen,
Merck Millipore, Germany) were routinely grown in LB
medium and maintained under standard conditions [37].
E. coli transformants were selected with 120 μg/mL ampi-
cillin and 34 μg/mL chloramphenicol as indicated. Protein
expression was carried out using EnPresso B medium
[29-31] including booster tablets following protocols pro-
vided by the manufacturer (BioSilta Oy, Finland). Unless
otherwise stated, chemicals and reagents were obtained
from Sigma-Aldrich or Roth (Carl Roth GmbH & Co. KG,
Germany).Plasmids
Plasmid pET-23d was obtained from Merck Millipore
(Germany) and plasmid pET23d(+)::HisDap was con-
structed encoding a diaminopeptidase-cleavable histidine-
tag [37]. DNA was prepared using the Roti®-Prep Plasmid
MINI kit (Carl Roth GmbH & Co. KG, Germany) and
DNA fragments were isolated from agarose gel blocks
employing the QIAquick Gel Extraction Kit (Qiagen,
Germany). Plasmid pMJS9 [16] was kindly provided by
Prof. Dr. L. W. Ruddock.
A gene sequence was designed to express amino acids
52–571 [8] of the human N-acetylgalactosaminyltransferase
2 [GalNT2, GeneID:2590, UniProtID:Q10471] and the re-
striction sites NdeI and XhoI were added at the 5′ and 3′
end of the DNA fragment, respectively. As a result, an
additional methionine residue followed by an alanine
moiety was added to the N-terminal sequence. The codon
usage of the gene fragment was adapted for expression in
an Escherichia coli strain background [38]. The synthesised
DNA fragment was purchased from GeneArt® Gene
Synthesis and supplied as plasmid construct cloned into
the pMK-RQ shuffle vector (Life Technologies GmbH,
Germany). Plasmid-DNA was digested with NdeI and
XhoI, the 1.8 kb fragment was isolated and ligated with
vector pET23d(+)::HisDap treated with the same restric-
tion enzymes. The DNA was subsequently used to trans-
form E. coli NovaBlue. As a result, the decahistidine-tag
with the sequence MAHHHHHQHQHQHQHQH was
translationally fused to the N-terminus of the expressed
protein thus facilitating purification of the product. The
resulting construct pET23d(+)::HisDapGalNAcT2 was
verified by restriction digests and the cloned fragment was
confirmed by DNA sequence analysis.Protein expression of HisDapGalNAcT2
Plasmid pET23d(+)::HisDapGalNAcT2 was first expressed
in Origami™ 2(DE3)pLysS and the production of insoluble
HisDapGalNAcT2 was detected. The bacterial suspension
was lysed by using ultrasonic sound. Afterwards the whole
cell lysate was centrifuged to separate the soluble fraction
(supernatant) from the particular fraction (cell pellet).
Whole cell lysate, supernatant and particulate fraction
were analysed by SDS-PAGE. Subsequent experiments
were carried out with E. coli SHuffle® T7 as strain
background.
Plasmids pET23d(+)::HisDapGalNAcT2 and pMJS9
were used to transform and co-transform the E. coli host
strain SHuffle® T7. Plasmid pMJS9 encodes the sulfhy-
dryl oxidase Erv1p and the protein disulfide isomerase
PDI under the control of the arabinose-promoter [16].
Transformants were grown on LB agar plates supple-
mented with the required antibiotics and a single colony
was used to inoculate a 2 mL liquid culture. Following in-
cubation, culture aliquots were frozen at −80°C employing
the CRYOBANK™ system (CRYOBANK™, Mast Diagnos-
tica GmbH, Germany). For expression experiments two
ceramic beads were transferred from a cryovial into a
50 mL Falcon tube containing 2 mL LB media (120 μg/
mL ampicillin, 34 μg/mL chloramphenicol and 0.2% glu-
cose) and the cells were maintained at 37°C, 175 rpm for
8 h. The culture was transferred into a 2 L baffled flask
containing 200 mL EnPresso B medium (120 μg/mL
ampicillin, 34 μg/mL chloramphenicol, 100 μL Reagent A)
and grown at 30°C, 175 rpm for 15 h. Booster solution
was added following the manufacturer’s instructions. The
pre-induction of the pMJS9 encoded gene products was
carried out in the presence of 0.5% w/v arabinose.
Isopropyl-β-D-thiogalactopyranosid (IPTG) was added
after 30 min to a final concentration of 1 mM to induce
expression of the glycosyltransferase HisDapGalNAcT2
and the culture was incubated at 30°C, 175 rpm for
23.5 h. The cells were harvested and 10 mL fractions were
pelleted via centrifugation at 4°C, 5500 g for 5 min. The
supernatants were discarded and the cell sediments
stored at −80°C. A scaled-up version of this experiment
was carried out and a 15 mL culture was prepared to in-
oculate 1.5 L expression medium in a 2 L bioreactor
(BIOSTAT®Bplus, Sartorius Stedim Biotech, Germany)
at 30°C, 60% pO2, 0.5 vvm, pH 7, adopting conditions
and procedures already described. Cell pellets were pooled
and stored at −80°C. A 7.98 g portion of the cell sediment
was used for protein purification.
Protein purification
A cell pellet derived from a 10 mL fraction of the ex-
pression culture was resuspended in 1.26 mL extraction
buffer (50 mM Tris, 300 mM NaCl; pH 8) containing
140 μL lysozyme, 3 μL DNAse and 50 μL protease
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Hoffmann La-Roche AG, Switzerland). The bacterial
suspension was cooled on ice for 30 min and sonicated
for 3 min on ice. The cell lysate was centrifuged at 4°C,
16 100 g for 10 min and the supernatant was passed
through a 0.45 μM filter. The polyhistidine-tagged protein
HisDapGalNAcT2 was purified using Ni-NTA spin col-
umns (Qiagen, Germany) with washing buffer (50 mM
Tris, 300 mM NaCl, 20 mM imidazole) and elution buffer
(50 mM Tris, 300 mM NaCl, 500 mM imidazole) adjusted
to pH 8 prior to use.
Similarly, 29 mL lysate were generated using a 7.98 g
portion of the previously isolated cell pellet. HisDapGal-
NAcT2 was purified on a HisTrap HP 1 mL column
with an ÄKTA Purifier (GE Healthcare Life Sciences).
The column was equilibrated with 8 column volumes
(CV) equilibration buffer (50 mM Tris, 300 mM NaCl;
pH 8) and the 29 mL sample was loaded, followed by 8
CV of washing buffer (50 mM Tris, 300 mM NaCl,
20 mM imidazole; pH 8). The protein was eluted
(50 mM Tris, 300 mM NaCl, 500 mM imidazole; pH 8)
using a linear gradient from 20 mM to 500 mM imid-
azole over 4 CV. 1 mL fractions were collected for fur-
ther analysis.
Analysis of purified protein
SDS-PAGE and immunoblot analyses were carried out
using standard protocols with dithiothreitol (DTT) as
reducing agent. Densitometric analysis was performed
employing Fusion-FX software (Vilber Lourmat, Germany).
For Western blot analysis, proteins were transferred to
polyvinylidene fluoride membranes (PVDF, Thermo Scien-
tific Inc., USA) and treated with mouse anti human
GALNT2 antibodies (H00002590-A01, Acris Antibody
GmbH, Germany) or penta-His antibodies (34660, Qiagen,
Germany). Binding was detected with horseradish peroxid-
ase (HRP)-labeled secondary antibodies and chemilumines-
cence was assessed using Roti®Lumin solutions.
Purified proteins were analysed by size exclusion chro-
matography coupled to multi-angle light scattering (SEC-
MALS) and circular dichroism (CD) spectroscopy to
determine molecular mass, size, aggregation state/disper-
sity, folding state and thermal transitions of the protein
[23,24]. Proteins were separated according to different
molecular masses using a size exclusion column (SEC)
(Yarra SEC-2000, Phenomenex Inc., Germany) on a
Multi-Angle static Light Scattering (MALS) detector
(Dawn®8+ HELEOS, 663.9 nm) in combination with an
ÄKTA Explorer (GE Healthcare Life Sciences) and protein
concentrations of the fractions were measured (Optilab®
T-rEX Refractive index detector, 658 nm, 25°C, and
ASTRA® Software, Wyatt Technology Europe GmbH,
Germany). 100 μL of the purified and filtrated samples
(0.2 μm, polyethersulfone membrane) were injected at aconcentration of 0.13 mg/mL in running buffer (50 mM
Tris, 300 mM NaCl, pH 8.0). Flow rate was adjusted to
0.5 mL/min.
Spectra of a filtered solution (NanoSep® MF 0.2 mM, Pall)
containing 0.2 mg/mL HisDapGalNAcT2 or rhGALNT2 in
20 mM sodium phosphate buffer (pH 7.3) were re-
corded in a 715 CD-spectropolarimeter (Jasco, Hachioji,
Japan) at 25°C. Spectra were measured from 190 – 260 nm
with wavelength steps of 0.1 nm and a scan speed of 50 nm
per minute. The averaged signal from four scans was
corrected for the buffer signal. Thermal transitions were
recorded at 208 nm with a step size of 0.1°C and a ther-
mal slope of 1°C per minute. The data was fitted using a
Boltzmann equation y ¼ A1‐A21þe x−x0ð Þ=dxþ A2 to obtain the
transition point (OriginPro 8, OriginLab, Northampton,
Massachusetts, USA).Protein activity assay
The activity of HisDapGalNAcT2 was monitored using a
glycosyltransferase activity kit (EA001, R&D Systems
Europe Ltd., United Kingdom) based on the release of
phosphate during transfer of glycosyl residues to an ac-
ceptor peptide. UDP-N-acetylgalactosamine was used as
donor substrate in combination with the acceptor sub-
strates mucin EA2 (Eurogentec SA Anaspec, Belgium)
comprising the peptide sequence PTTDSTTPAPTTK
[10] or Filgrastim (Neupogen®, Amgen Inc.). Prior to
use, the elution buffer of the purified HisDapGalNAcT2
(50 mM Tris, 300 mM NaCl, 500 mM imidazole; pH 8)
was exchanged by 25 mM Tris, 150 mM NaCl, pH 7.3.
The protein sample was stored at 4–8°C for about
3 weeks. Control assays were carried out using purified
rhGALNT2 isolated from murine myeloma NS0 cells
(7507-GT-020, R&D Systems Europe Ltd., United King-
dom). The enzyme was provided by the manufacturer in
25 mM Tris, 150 mM NaCl, 0.05% w/v Brij-35; pH 7.5
and stored in the freezer at −80°C.
Samples with EA2 as acceptor substrate were desalted,
concentrated (ZipTip®μC18, Millipore, USA) and embed-
ded into a HCCA matrix (α-cyano-4-hydrosycinnamic
acid) for subsequent MALDI-TOF-MS analysis. Filgrastim
samples were digested with trypsin prior to Electrospray
Ionisation Mass Spectrometry (ESI-MS). Both analyses
were carried out at the life science center of the University
of Hohenheim (Germany).
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